What is Avalo Therapeutics's remainder of fiscal year 2024?

Avalo Therapeutics (AVTX) reported remainder of fiscal year 2024 of $282K in Q1 2026.

How has Avalo Therapeutics's remainder of fiscal year 2024 changed year-over-year?

Avalo Therapeutics's remainder of fiscal year 2024 decreased by 32.9% year-over-year, from $420K to $282K.

Avalo Therapeutics AVTX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

ImmunityBio, Inc.IBRX

——

Oruka Therapeutics, Inc.ORKA

——

Aurinia PharmaceuticalsAUPH

——

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's remainder of fiscal year 2024?: Avalo Therapeutics (AVTX) reported remainder of fiscal year 2024 of $282K in Q1 2026.
How has Avalo Therapeutics's remainder of fiscal year 2024 changed year-over-year?: Avalo Therapeutics's remainder of fiscal year 2024 decreased by 32.9% year-over-year, from $420K to $282K.